Elizabeth M Bald1, Christopher S Nance2, Jordan L Schultz3. 1. Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah. 2. Department of Neurology, Carver College of Medicine at the University of Iowa, Iowa City, Iowa. 3. Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa.
Abstract
INTRODUCTION: We utilized the Pooled Resource Open-Access Clinical Trials (PRO-ACT) database to investigate whether melatonin use among patients with amyotrophic lateral sclerosis (ALS) was associated with slower disease progression and prolonged survival. METHODS: This retrospective analysis of the PRO-ACT database addresses the impact of melatonin on progression and overall survival of ALS. A Cox proportional hazards ratio model was performed to investigate the effect that melatonin had on time to death. For secondary outcome measures, linear mixed effects regression models were used to ascertain the effect of melatonin on change in standardized ALS Functional Rating Scale (sALSFRS) and percentage predicted forced vital capacity (FVC) scores. RESULTS: Melatonin users had a significantly decreased annualized hazard death rate compared with the non-melatonin users (hazard ratio, 0.241; 95% confidence interval, 0.088-0.659; P = .0056). The melatonin users also had a slower rate of decline in sALSFRS score (t = 2.71; P = .0069) and change in percent predicted FVC score (t = 2.94; P = .0035) compared with the non-melatonin users. DISCUSSION: Our findings suggest that melatonin may be beneficial for patients with ALS. Due to the nature of this database, our results are solely intended to be hypothesis-generating and no strong associations can be made. Given the low cost and favorable safety profile of melatonin, the hypotheses generated warrant further investigation.
INTRODUCTION: We utilized the Pooled Resource Open-Access Clinical Trials (PRO-ACT) database to investigate whether melatonin use among patients with amyotrophic lateral sclerosis (ALS) was associated with slower disease progression and prolonged survival. METHODS: This retrospective analysis of the PRO-ACT database addresses the impact of melatonin on progression and overall survival of ALS. A Cox proportional hazards ratio model was performed to investigate the effect that melatonin had on time to death. For secondary outcome measures, linear mixed effects regression models were used to ascertain the effect of melatonin on change in standardized ALS Functional Rating Scale (sALSFRS) and percentage predicted forced vital capacity (FVC) scores. RESULTS: Melatonin users had a significantly decreased annualized hazard death rate compared with the non-melatonin users (hazard ratio, 0.241; 95% confidence interval, 0.088-0.659; P = .0056). The melatonin users also had a slower rate of decline in sALSFRS score (t = 2.71; P = .0069) and change in percent predicted FVC score (t = 2.94; P = .0035) compared with the non-melatonin users. DISCUSSION: Our findings suggest that melatonin may be beneficial for patients with ALS. Due to the nature of this database, our results are solely intended to be hypothesis-generating and no strong associations can be made. Given the low cost and favorable safety profile of melatonin, the hypotheses generated warrant further investigation.
Authors: Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander Journal: Neurobiol Dis Date: 2013-03-26 Impact factor: 5.996
Authors: Albert A Taylor; Christina Fournier; Meraida Polak; Liuxia Wang; Neta Zach; Mike Keymer; Jonathan D Glass; David L Ennist Journal: Ann Clin Transl Neurol Date: 2016-09-07 Impact factor: 4.511
Authors: Elena Obrador; Rosario Salvador-Palmer; Rafael López-Blanch; Ali Jihad-Jebbar; Soraya L Vallés; José M Estrela Journal: Int J Mol Sci Date: 2021-06-14 Impact factor: 5.923